The company is increasing its expected reported sales to a new range of $3.6B-$3.7B from $3.5B-$3.6B due to changes in foreign exchange rates. This outlook reflects the current state of tariffs and trade policy. FY25 consensus $3.57B.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- XRAY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Dentsply Sirona price target lowered to $16 from $20 at Piper Sandler
- Dentsply Sirona price target lowered to $16 from $18 at Mizuho
- Dentsply Sirona downgraded to Equal Weight at Morgan Stanley
- Dentsply Sirona downgraded to Equal Weight from Overweight at Morgan Stanley